Be Fraud Aware: By staying vigilant, you can help yourself from being the victim of fraud.

Back

Overview Wealth Planning Service Discretionary Investment Service Other Investment Services
Overview Investment Solutions Pension Solutions SDIO Application Forms – Intermediaries
Overview

Cantor Fitzgerald Asset Management

Overview Market Updates Useful Forms Sustainability Disclosures
Fund Centre

Multi-Asset Funds

Overview Multi-Asset 70 Fund Multi-Asset 50 Fund Multi-Asset 30 Fund Balanced Fund

Equity Funds

Overview Irish Equity Fund International Equity Fund International Equity UCITS Fund Global Equity Income Fund

ESG/Ethical Funds

Overview Green Effects Fund Paris Aligned Global Equity Fund Ethical Fund Ethical International Fund

Thematic Funds

Overview Technology Fund Infrastructure Impact Fund New Haven Housing Fund

Alternative Investment Fund

Alternative Investment Fund (RIAIF)

Fixed Income & Cash Funds

Overview Cash Fund Long Bond Fund Fixed Interest Fund
Overview

Corporate

Overview

Real Estate

Overview Capital Markets & Advisory

Credit Unions

Overview Investment Advisory Services
Debt Capital Markets Probate Services
Dedicated to institutional wealth, stakeholder value, and a sustainable future

Dedicated to institutional wealth, stakeholder value, and a sustainable future

Overview Investment Services Stewardship
Supportive of you, your custodial 
vision, and your philanthropic goals

Supportive of you, your custodial 
vision, and your philanthropic goals

Weekly Trader and Bond Markets 24.02.2025 – Kerry Group, Bank of Ireland & Roche

24.02.2025



Opportunities this week:

  • Last week, following Kerry’s FY24 earnings which came out broadly in line with expectations for its Taste & Nutrition division, we increased our price target on the stock to €116 (19% upside) while also adding it to our analyst conviction list.
  • This morning Bank of Ireland reported its FY2024 earnings that show a slight beat on net interest income and underlying profit after tax. BUY PT: €10.80.
  • Following on from Roche’s recent Immunology/Nephrology seminar, on Thursday the company presented a launch update on its groundbreaking Sequencing by Expansion (SBX) technology. BUY PT: CHF 330.